Jitendra – Page 21 – Scilex Holding

09 Apr

Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion

July 15, 2021
Posted by Jitendra

Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for...

31 Mar

SEC FIlings

Annual report for fiscal year ending Dec 31, 2020

November 17, 2022
Posted by Jitendra

08 Mar

SEC FIlings

Statement of acquisition of beneficial ownership by individuals

November 17, 2022
Posted by Jitendra

01 Mar

Press Release

Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome

July 15, 2021
Posted by Jitendra

SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with...

02 Feb

Publications